(WASHINGTON, DC) – Consumer Healthcare Products Association (CHPA) President and CEO, Scott Melville, today released the below statement following congressional passage of a short-term spending package to fund the Federal Government through Dec. 16. Included in this Continuing Resolution is legislation to reauthorize the U.S. Food and Drug Administration’s (FDA) user fee programs for prescription drugs, generic drugs, biosimilars, and medical devices over the next five years.
“CHPA applauds the passage of today’s legislation which ensures FDA has the resources and funding necessary to continue its critical work of protecting American consumers and our nation’s public health.
“While we look forward to the President signing this bill into law, there is still more work to be done, including providing FDA with the tools it needs to further improve its ability to regulate the rapidly growing dietary supplement industry. CHPA has appreciated the robust dialogue surrounding the modernization of supplement regulations, and we look forward to continuing to work with stakeholders and Congress in support of comprehensive reform.”
